Literature DB >> 24649315

Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy.

Susumu Saigusa1, Yasuhiro Inoue1, Koji Tanaka1, Yoshinaga Okugawa1, Yuji Toiyama1, Keiichi Uchida1, Yasuhiko Mohri1, Masato Kusunoki1.   

Abstract

Preoperative chemoradiotherapy (CRT) is an effective tool for local control that functions by inducing cancer cell apoptosis and inhibiting cell growth. The aim of this study was to evaluate the expression of caspase-cleaved keratin 18 cytoskeletal protein, M30, which is known as an apoptotic marker in residual rectal cancer following preoperative CRT. A total of 72 patients with rectal cancer who had undergone preoperative CRT were enrolled in this study. Immunostaining with M30 cytodeath antibody was performed and the correlation between M30 staining and clinicopathological variables was analyzed. Furthermore, we examined the correlation of M30 staining with the expression of Bax, Bcl-2, Ki67 and PCNA using transcriptional and immunohistochemical analyses. The results showed that 34 (47%) patients were positive for M30 staining. Lack of M30 expression was significantly correlated with advanced T stage, postoperative stage and tumor recurrence (P<0.05). Patients with M30 staining had better recurrence-free survival (RFS) than those without it (P=0.0301). In the immunohistochemical analysis, residual cancer cells with M30 staining lacked Ki67 expression. No significant correlation was observed between M30 positivity and the gene expression of apoptotic and proliferative markers. In conclusion, findings of the present study suggested that the evaluation of M30 expression may be useful in the prediction of tumor recurrence in rectal cancer patients who have been treated with preoperative CRT.

Entities:  

Keywords:  M30; apoptosis; preoperative chemoradiotherapy; rectal cancer; tumor recurrence

Year:  2013        PMID: 24649315      PMCID: PMC3916157          DOI: 10.3892/mco.2013.189

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  23 in total

1.  Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.

Authors:  Krzysztof Bujko; Wojciech Michalski; Lucyna Kepka; Marek P Nowacki; Anna Nasierowska-Guttmejer; Piotr Tokar; Dariusz Dymecki; Mariusz Pawlak; Tadeusz Lesniak; Piotr Richter; Andrzej Wojnar; Ewa Chmielik
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-21       Impact factor: 7.038

Review 2.  Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.

Authors:  F M Smith; J V Reynolds; N Miller; R B Stephens; M J Kennedy
Journal:  Eur J Surg Oncol       Date:  2005-12-01       Impact factor: 4.424

3.  Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  R Ryan; D Gibbons; J M P Hyland; D Treanor; A White; H E Mulcahy; D P O'Donoghue; M Moriarty; D Fennelly; K Sheahan
Journal:  Histopathology       Date:  2005-08       Impact factor: 5.087

4.  Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer.

Authors:  A S Dhadda; P Dickinson; A M Zaitoun; N Gandhi; E M Bessell
Journal:  Eur J Cancer       Date:  2011-01-08       Impact factor: 9.162

5.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

6.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

7.  Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy.

Authors:  G C Adell; H Zhang; S Evertsson; X F Sun; O H Stål; B A Nordenskjöld
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

8.  Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours.

Authors:  M J E M Gosens; R C Dresen; H J T Rutten; G A P Nieuwenhuijzen; J A W M van der Laak; H Martijn; I Tan-Go; I D Nagtegaal; A J C van den Brule; J H J M van Krieken
Journal:  Ann Oncol       Date:  2008-07-29       Impact factor: 32.976

9.  Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.

Authors:  Susumu Saigusa; Koji Tanaka; Yuji Toiyama; Takeshi Yokoe; Yoshinaga Okugawa; Yasuhiro Ioue; Chikao Miki; Masato Kusunoki
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

10.  Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas.

Authors:  J J Koornstra; F E M Rijcken; S De Jong; H Hollema; E G E de Vries; J H Kleibeuker
Journal:  Histopathology       Date:  2004-01       Impact factor: 5.087

View more
  4 in total

1.  Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.

Authors:  Susumu Saigusa; Yuji Toiyama; Koji Tanaka; Yasuhiro Inoue; Koichiro Mori; Shozo Ide; Hiroki Imaoka; Mikio Kawamura; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int J Clin Oncol       Date:  2016-02-26       Impact factor: 3.402

2.  Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.

Authors:  Susumu Saigusa; Yuji Toiyama; Koji Tanaka; Yasuhiro Inoue; Koichiro Mori; Shozo Ide; Hiroki Imaoka; Mikio Kawamura; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int J Clin Oncol       Date:  2015-09-14       Impact factor: 3.402

3.  A patient tumour-on-a-chip system for personalised investigation of radiotherapy based treatment regimens.

Authors:  R Kennedy; D Kuvshinov; A Sdrolia; E Kuvshinova; K Hilton; S Crank; A W Beavis; V Green; J Greenman
Journal:  Sci Rep       Date:  2019-04-19       Impact factor: 4.379

4.  Evaluation of renal injury caused by acute volume replacement with hydroxyethyl starch 130/0.4 or Ringer's lactate solution in pigs.

Authors:  David A Ferreira; Rita Cruz; Carlos Venâncio; Ana I Faustino-Rocha; Aura Silva; João R Mesquita; Ana L Ortiz; Helena Vala
Journal:  J Vet Sci       Date:  2018-09-30       Impact factor: 1.672

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.